Novo Nordisk A/S Sponsored ADR (NVO)
Summary
Novo Nordisk: The Oral Wegovy Promise
Novo Nordisk has made robust gains of 40% at the stock markets since April, supported by the success of oral Wegovy and attractive valuations. The Wegovy pill can see a nice revenue uptick in Q2 2026 going by recent data, and that can continue into the year as it gains approvals from international markets. Importantly, the pill has made gains even when competitor Eli Lilly's Foundayo has seen limited success, which can give Novo Nordisk a much-needed boost.
Novo Nordisk (NVO) Ascends While Market Falls: Some Facts to Note
Novo Nordisk (NVO) closed the most recent trading day at $51.48, moving +1.82% from the previous trading session.
NVO Stock Up on EC Approval of Wegovy Pill to Treat Obesity
Novo Nordisk wins EC approval for a once-daily oral Wegovy pill for obesity, expanding its EU franchise with the first GLP-1 tablet for weight management.
Novo Nordisk A/S Sponsored ADR Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| TJD Thomas John Drogan PR Inc.IPAL SECURITIES Inc. | 32,637 | $3.7M | $1.66M | -$2.04M | -55.23% |
| DI David Izzi Brown, LISLE/CUMMINGS Inc. | 59,095 | $4.3M | $3M | -$1.3M | -30.2% |
| TMB Timothy M. Bidwell Hazlett, BURT & WATSON Inc. | 10,709 | $864,307.74 | $543,588.84 | -$320,718.9 | -37.11% |
| CE Curtis Ellergodt Rothschild Investment LLC | 11,935 | $1.03M | $605,820.6 | -$420,830.32 | -40.99% |
| WH William Herlihy RESOURCES MANAGEMENT Corp. /CT/ /ADV | 13,000 | $1.67M | $659,880 | -$1.01M | -60.47% |
Novo Nordisk A/S Sponsored ADR (NVO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Novo Nordisk A/S Sponsored ADR ever had a stock split?
Novo Nordisk A/S Sponsored ADR Profile
| Health Care Providers & Services Industry | Healthcare Sector | Maziar Mike Doustdar CEO | NYSE Exchange | 670100205 CUSIP |
| DK Country | 77,406 Employees | 8 Apr 2026 Last Dividend | 20 Sep 2023 Last Split | - IPO Date |
Overview
Novo Nordisk A/S is an established global pharmaceutical company with a heritage dating back to 1923. With its headquarters in Bagsvaerd, Denmark, the company has a widespread operational reach across Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and other international markets. Novo Nordisk is committed to discovering and developing innovative pharmaceutical products, focusing primarily on Diabetes and Obesity Care, and Rare Disease. The company has carved a niche for itself by not just being a manufacturer but also engaging in the research and development of new pharmaceutical products, ensuring they provide contemporary and efficient solutions to the healthcare challenges of today.
Products and Services
Novo Nordisk A/S offers a comprehensive range of healthcare products and solutions aimed at addressing some of the most challenging diseases. With a focus on quality and innovation, their offerings encompass:
- Diabetes and Obesity Care: This segment includes products specifically designed to manage diabetes and obesity, along with related cardiovascular conditions and other emerging therapeutic areas. The company’s commitment to combating diabetes and obesity is reflected in its continuous pursuit of safer and more effective treatments.
- Rare Disease: Novo Nordisk takes a targeted approach to rare diseases, focusing on rare blood disorders, rare endocrine disorders, and providing hormone replacement therapy. These specialized treatments are developed with the aim of addressing medical needs that are often underserved, demonstrating the company's dedication to all patients, regardless of the rarity of their condition.
- Insulin Pens: The company produces a variety of insulin pens that are designed for ease of use, ensuring that patients can manage their condition with confidence and precision. These devices are a testament to Novo Nordisk’s focus on patient-centric innovations.
- Growth Hormone Pens: These pens are part of the portfolio intended for patients requiring growth hormone therapy. They simplify the administration process, making treatment more accessible and manageable for patients.
- Injection Needles: To complement their insulin and growth hormone pens, Novo Nordisk also supplies high-quality injection needles, designed for minimal discomfort and optimal medication delivery.
- Smart Solutions for Diabetes: Innovating beyond conventional treatments, Novo Nordisk offers smart insulin pens and Dose Check, an insulin dose guidance application. These smart solutions enhance the treatment experience by integrating advanced technology with patient care, facilitating better management of diabetes.
Through a collaboration agreement with Aspen Pharmaceuticals, Novo Nordisk also ensures the production of insulin products, highlighting their commitment to making essential medications accessible. The company's enduring legacy and forward-looking approach have positioned it as a key player in the global pharmaceutical industry, dedicated to improving the lives of patients worldwide.
